COVID-19 and Acute Coronary Syndromes: From Pathophysiology to Clinical Perspectives

Table 1

Ongoing randomized clinical trials investigating antithrombotic regimens in patients with COVID-19.

Study name	Registration number	Population	Treatments	Design	Estimated enrollement ()	Primary endopoint	Time of FU (days)
PARTISAN	NCT04445623	Non-ICU patients	Prasugrel 10 mg	Randomized, double blind	128	P/F ratio	7
PEAC	NCT04365309	Non-ICU patients	Aspirin 100 mg	Randomized, open label	128	Clinical recovery time; The time of SARS-CoV2 overcasting	14; 37
ACT-COVID19	NCT04324463	Non-ICU patients	Aspirin; Rivaroxaban; Colchicine	Randomized, open label, factorial	4000	Colchicine vs. control; aspirin and rivaroxaban vs. control: (i) Composite of invasive mechanical ventilation or death; (ii) Disease progression of 2 points on a 7-point scale; Aspirin and rivaroxaban vs. control: (i) Composite of MACE (MI, stroke, acute limb ischemia, VTE, death)	45
C-19-ACS	NCT04333407	Non-ICU patients	Aspirin 75 mg; Clopidogrel 75 mg; Rivaroxaban 2.5 mg; Atorvastatin 40 mg; Omeprazole 20 mg	Randomized, open label	3170	All-cause mortality	30
RESIST	CTRI/2020/07/026791	Non-ICU patients	Aspirin 75 mg; Atorvastatin 40 mg	Randomized, open label	800	Clinical deterioration expressed as progression of	10
COVID-PACT	NCT04409834	ICU patients	UFH iv enoxaparin 1 mg/kg; Clopidogrel 75 mg; UFH sc; Enoxaparin 40 mg/0.4 mL	Randomized, open label, factorial	750	Hierarchical composite: death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism, or acute limb ischemia or clinically silent DVT	28

COVID-19: coronavirus disease 2019; DVT: deep vein thrombosis; ECMO: extra corporeal membrane oxygenation; ICU: intensive care unit; MACE: major adverse cardiovascular events; MI: myocardial infarction; P/F: PaO2/FiO2; RRT: renal replacement therapy; SARS-CoV2: severe acute respiratory syndrome coronavirus 2; UFH: unfractionated heparin; VTE: venous thromboembolism.